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Cardio classics revisited – focus on the role  
of candesartan
Abstract: Angiotensin II receptor blockers (ARBs) are antihypertensive agents with considerable 
evidence of efficacy and safety for the reduction of cardiovascular (CV) disease risk in numerous 
patient populations across the CV continuum. There are several agents within this class, all of which 
have contributed to various degrees, to this evidence base. The evidence with ARBs continues to 
accumulate, with ongoing trials investigating their role in additional patient populations, potentially 
expanding their efficacy across a broad spectrum of CV disease states. Cardiovascular disease 
(CVD) is a leading cause of death around the world, accounting for approximately 29.2% of total 
global deaths. Of all the deaths attributed to CVD, approximately 43% are due to ischemic heart 
disease, 33% to cerebrovascular disease, and 23% to hypertensive and other heart conditions. CVD 
has been represented as a “CV continuum”. This continuum concept can be used to describe CVD 
in general or in specific vascular beds (eg, coronary artery disease or cerebrovascular disease). This 
review article will discuss the results of the landmark ARB candesartan clinical trials published 
over the past decade. The evidence presented spans the entire CV continuum, including the effects 
of ARBs in at-risk patients, stroke, myocardial infarction (MI), and heart failure (HF), as well as a 
brief discussion of ongoing trials.
Keywords: candesartan, cardiovascular disease, angiotensin II receptor blockers
Angiotensin II receptor blockers (ARBs) for 
cardioprotection in at-risk patients
There have been several large comparative clinical trials examining the impact of ARB 
therapy on cardiovascular (CV) morbidity and mortality in at-risk patients (Table 1).
In the LIFE study, the difference in the composite endpoint was largely driven by 
a significant difference in stroke between the two groups (25% relative risk reduction 
[RRR]; adjusted hazard ratio [HR] 0.75, 95% confidence interval [CI]: 0.63–0.89; 
P = 0.001)1 (Figure 2).
In SCOPE, there was a statistically significant mean difference between the 
  treatment groups in adjusted blood pressure (BP) reduction: 3.2/1.6 mmHg in favor 
of the candesartan group (P , 0.001). While no statistically significant risk reduction 
for the primary endpoint was observed (RRR: 10.9%; 95% CI: -6.0–25.1, P = 0.19), a 
significant 27.8% RRR for nonfatal stroke (P = 0.04) and nonsignificant 23.6% RRR 
in all stroke (P = 0.056) in favor of candesartan were reported.2
In the VALUE trial, BP was significantly lower with amlodipine after 1 month 
(4.0/2.1 mmHg difference compared to valsartan, P , 0.001) and after 1 year   
(1.5/1.3 mmHg difference compared to valsartan; P , 0.001).3–5
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Valsartan was further evaluated in the JIKEI-HEART 
study, the incidence of the composite endpoint was 6.0% in 
the valsartan group and 9.7% in the non-ARB group, for a 
RRR of 39% with valsartan (HR 0.61, 95% CI: 0.47–0.79, 
P = 0.0002)6,7 (Figure 3).
Most recently, two large, parallel studies evaluating the 
cardioprotective effects of telmisartan have been published: 
ONTARGET and TRANSCEND trials.8,9
ONTARGET demonstrated that telmisartan was non-
inferior to ramipril, with no significant difference in the 
proportion of patients experiencing the primary endpoint 
(relative risk [RR] 1.01; 95% CI: 0.94–1.09; Figure 
4). InTRANSCEND study in the secondary composite 
  endpoint of CV death, mycardial infarction (MI) and stroke, 
telmisartan therapy was   associated with a 13% RRR com-
pared to placebo (HR 0.87, 95% CI: 0.76–1.00, P = 0.048   
unadjusted.9
Effect of ARBs on specific conditions 
along the CV continuum
The following section documents the efficacy data for ARBs 
in studies examining more specific patient populations, 
including those with more advanced disease (eg, post-MI, 
stroke, and heart failure; Table 1).
Post-stroke
Clinical trial data support the ability of ARBs to prevent 
stroke in various populations.
In the MOSES study, the reduction in subsequent 
  cerebrovascular events also favored eprosartan (IDR 0.75; 
95% CI: 0.58–0.97; P = 0.03). BP was similar in both treat-
ment arms at the end of the study.10
In the PRoFESS study, 8.7% of patients in the telmisartan 
group and 9.2% of those in the placebo group had a recurrent 
stroke (the primary endpoint). However, the between-group 
difference was not statistically significant (HR 0.95; 95% CI: 
0.86–1.04; P = 0.23).11
Myocardial ischemia and infarction
In the OPTIMAAL study, the investigators reported no 
significant difference in the primary endpoint between 
the treatment groups. But it remains unknown whether 
losartan is noninferior to captopril in this patient   
population.12
In the VALIANT study, in the primary endpoint analysis 
(all-cause mortality), valsartan met a priori defined criteria 
for non-inferiority compared to captopril (HR 1.00; 97.5% 
CI: 0.90–1.11; P = 0.98) (Figure 5).13 The VALIANT investi-
gators also included an imputed placebo analysis designed to 
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evaluate their findings in the context of the placebo-controlled 
results of the Survival and Ventricular Enlargement (SAVE) 
trial, which evaluated captopril,14 and two other similarly 
designed ACE inhibitor trials, which tested ramipril and tran-
dolapril in the post-MI setting (the Acute Infarction Ramipril 
Efficacy [AIRE] trial and the Trandolapril Cardiac Evaluation 
[TRACE] trial, respectively).15,16 The two monotherapies 
were also found to have equivalent effects on other major 
CV endpoints (eg, MI, stroke).17
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Figure 2 Kaplan-Meier curves for the primary composite endpoint in the life study: 
losartan vs atenolol in patients with hypertension and LVH. Copyright © 2002, 
elsevier. Adapted with permission from Dahlöf B, Devereux RB, Kjeldsen Se, et al. 
Cardiovascular morbidity and mortality in the Losartan intervention For endpoint 
reduction in hypertension study (LiFe): a randomised trial against atenolol. Lancet. 
2002;359(9311):995–1003.
Abbreviation: Ci, confidence interval.
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Figure 3 Kaplan-Meier curves of the cumulative frequency of the combined primary 
endpoint (cv morbidity and mortality) in the jikei heart study: valsartan vs non-ARB 
treatment. Copyright © 2007, elsevier. Adapted with permission from Mochizuki S, 
Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and 
other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded 
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Figure  5  Kaplan-Meier  estimates  of  the  rate  of  death  from  any  cause  in  the 
VALiANT  Study:  valsartan,  captopril  or  their  combination  in  Post-Mi  patients. 
Copyright © 2003, Massachusetts Medical Society. Adapted with permission from 
Pfeffer MA, McMurray JJ, Velazquez eJ, et al. Valsartan, captopril, or both in myocardial 
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Abbreviations: VALiANT, Valsartan in Acute Myocardial Infarction; CI, confidence 
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Figure 4 Kaplan-Meier curves for the primary outcome (death from CV causes, Mi, 
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events. N Engl J Med. 2008;358(15):1547–1559.
Abbreviations: ONTARGeT, Ongoing Telmisartan Alone and in Combination 
with Ramipril Global Endpoint Trial; CI, confidence interval.
Heart failure (HF)
The ELITE II study18 sought to validate the findings of 
ELITE,19 a study in which low-dose losartan was unexpectedly 
found to be superior to captopril for the reduction of mortal-
ity in patients with HF (a secondary endpoint of ELITE). 
This trial was designed as a superiority study and was not 
designed to show equivalence; thus, whether or not an ARB is 
as protective as an ACE inhibitor in HF remained unanswered 
by ELITE II.
In the Val-HeFT study, there was no significant difference 
in all-cause mortality between the two treatment arms (RR 
1.02; 98% CI: 0.88–1.18; P = 0.80).20
The Candesartan in Heart failure Assessment of 
  Reduction in Mortality and Morbidity (CHARM) study 
program21 consisted of a series of separate randomized, 
controlled studies designed to investigate the benefits of 
candesartan in three distinct populations of patients with 
symptomatic HF: those with systolic dysfunction who were 
receiving ACE inhibitors (CHARM-Added, n = 2,548),22 
those with systolic   dysfunction who were intolerant of 
ACE   inhibitors (CHARM-  Alternative, n = 2,028)23 and 
those with   preserved left ventricular (LV) systolic function 
with or without background ACE inhibitor use (CHARM-
Preserved, n = 3,023).24 The primary   objective in each trial 
was to evaluate the effects of   candesartan on the combined 
primary endpoint of CV mortality or congestive heart failure 
(CHF) hospitalization.
After a median follow up of 41 months in the CHARM-
Added trial, 38% of those in the candesartan group expe-
rienced a primary event compared to 42% in the placebo 
group.22 The RRR for candesartan (on top of the benefit 
the patients were already receiving from ACE inhibition) 
was 15% compared to placebo (unadjusted HR 0.85; 95% 
CI: 0.75–0.96; P = 0.011). The results for each of the com-
ponents of the primary endpoint were also significantly 
in favor of candesartan; the RRR was 16% for CV death 
(unadjusted HR 0.84; 95% CI: 0.72–0.98; P = 0.029) and 
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17% for HF hospitalization (unadjusted HR 0.83; 95% 
CI: 0.71–0.96; P = 0.014). This study further supports the 
concept introduced by Val-HeFT that adding an ARB to 
ACE inhibition may provide benefit in patients with HF and 
systolic dysfunction.
Over a median follow up of 33.7 months in the 
CHARM-Alternative trial, the RRR for the primary 
composite outcome was 23% in favor of candesartan 
(unadjusted HR 0.77; 95% CI: 0.67–0.89; P = 0.0004; 
Figure 6).23 This finding appears to have been driven pri-
marily by a reduction in HF hospitalizations, for which the 
RRR was 32% (unadjusted HR 0.68; 95% CI: 0.57–0.81; 
P , 0.0001).
In the CHARM-Preserved study, there was no significant 
difference in the primary endpoint between the two treatment 
arms over a median follow up of 36.6 months (unadjusted 
HR 0.89; 95% CI: 0.77–1.03; P = 0.118).24
In I-PRESERVE, there was no significant difference in the 
primary composite outcome between irbesartan and placebo 
(HR 0.95; 95% CI: 0.86–1.05; P = 0.35).25
Although ARBs have been shown to be effective for 
treating patients with established HF, they have not shown 
such an effect in its prevention.26
Ongoing ARB studies
Clinical trials have clearly demonstrated the efficacy 
of ARBs throughout the CV continuum. Additionally, 
  studies are ongoing investigating the utility of ARBs in 
several patient populations in which the efficacy of ARBs 
is   currently unknown or inadequately investigated.27–35 
Table 2 Ongoing ARB trials with primary CV endpoints across the CV continuum
Study name ARB Study population n (approx.) Primary endpoint(s) Novelties
ACTiVe-i27 irbesartan Atrial fibrillation and $1 risk 
factor for stroke
9,000 Composite of CV events (stroke, non-CNS 
systemic embolism, Mi, or vascular death)
CORAL28 Candesartan Renal artery stenosis 1,080 Composite CV and renal endpoint: CV or  
renal death, Mi, hospitalization for CHF, 
stroke, doubling of serum creatinine, and 
need for renal replacement therapy
KYOTO HeART29 Valsartan High-risk hypertension 3,000 Composite of CV/renal events (stroke, TiA, 
Mi, HF, angina, dissecting aortic aneurysm, 
lower limb arterial obstruction, emergency 
thrombosis, transition to dialysis or 
doubling of serum creatinine)
NAGOYA HeART30 Valsartan Hypertension with diabetes  
or impaired glucose tolerance
3,000 Fatal or nonfatal Mi, fatal or nonfatal 
stroke, admission due to CHF, coronary 
revascularization, sudden cardiac death
NAViGATOR31 Valsartan impaired fasting glucose 9,518 Progression to diabetes; extended CV 
composite (CV death, nonfatal Mi, 
nonfatal stroke, hospitalization for HF, 
revascularization or hospitalization for 
unstable angina); core CV composite  
(CV death, nonfatal Mi, nonfatal stroke,  
or hospitalization for HF)
ROADMAP32 Olmesartan Type 2 diabetes with 
normoalbuminuria
4,400 Occurrence of microalbuminuria (CV 
morbidity and mortality as secondary 
endpoint)
SCAST33 Candesartan Acute stroke 2,500 Death or disability at 6 months; 
combination of vascular death, myocardial 
infarction, or stroke during the first  
6 months
VALiSH34 Valsartan isolated systolic hypertension 3,000 Composite of CV events (sudden death, 
fatal or nonfatal stroke, fatal or nonfatal 
Mi, death due to HF, other CV death, 
unplanned hospitalization for CV disease, 
and renal disorder)
VART35 Valsartan Hypertension 797 CV morbidity and mortality
Abbreviations: ACTIVE-I, atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events; CORAL, cardiovascular outcomes in renal atherosclerotic 
lesions; NAGOYA HeART, novel antihypertensive goal of hypertension with diabetes – hypertensive events and ARB treatment; NAViGATOR, nateglinide and valsartan 
in impaired glucose tolerance outcomes research; ROADMAP, randomized olmesartan and diabetes microalbuminuria prevention; SCAST, Scandinavian candesartan acute 
stroke trial; VALiSH: valsartan in elderly isolated systolic hypertension; VART, valsartan amlodipine randomized trial; CNS, central nervous system; CV, cardiovascular;   
Mi, myocardial infarction; HF, heart failur; CHF, congestive heart failure; TiA, transient ischemic attack.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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These key ongoing studies are summarized in Table 
2, along with their   significance in the CV continuum. 
Additionally, there are newer therapeutic approaches to 
suppress the RAS system through direct renin inhibition. 
Currently, a comprehensive clinical trial program known 
as ASPIRE-HIGHER, is   evaluating the effects of the direct 
renin inhibitor, aliskiren, on various CV and cardio-renal 
endpoints.36
Role of candesartan: indications for 
this angiotensin II receptor blocker
Binding characteristics of the AT1-
receptor blockers at the AT1 receptor
Candesartan cilexetil, is administered in an inactive form 
and is rapidly and completely converted to the active 
drug, candesartan, during gastrointestinal absorption. In 
vitro studies have shown that candesartan has the   highest 
  receptor affinity of all the available AT1-receptor   blockers 
and is not displaced from the receptor by high concentra-
tions of angiotensin II. The tight and long-lasting binding 
of candesartan to the AT1-receptor provides effective 
blockade of the negative cardiovascular effects of angio-
tensin II.
Candesartan  reduces  the  maximal  response  to 
angiotensin II, and can almost completely abolish the 
response; this inhibition cannot be overcome by increas-
ing concentrations of angiotensin II and hence is described 
as insurmountable inhibition.37,38 It results from fast and 
reversible binding of the antagonist to the receptor, whereas 
fully insurmountable   inhibition, as with candesartan, is 
related to slow dissociation of the receptor–antagonist 
complex.38 In other studies,   reversal of the inhibitory effect 
of candesartan in CHO cells was slower than with irbesar-
tan or EXP-31748, while the effect of losartan was almost 
instantaneously reversible, suggesting that insurmountable 
antagonism is related to prolonged   binding of the antagonist 
to the receptor.39
The potent AT1-receptor blockade produced by 
  candesartan and EXP-3174 appears to be related to the 
  presence of two negatively charged groups, a carboxyl 
group and a tetrazole moiety: the less potent precursors of 
these molecules, candesartan cilexetil and losartan, pos-
sess only the tetrazole moiety.38 Other potent AT1-receptor 
blockers also appear to be diacidic molecules.38 Experi-
ments with candesartan analogues suggest that appropri-
ate alignment of the carboxylgroups is a prerequisite for 
tight and prolonged binding,and hence for insurmountable 
antagonism.38
Tolerability
The long-term efficacy and tolerability of candesartan 
 cilexetil was assessed in two open-label, prospective multi-
centered studies in patients with mild to moderate essential 
hypertension.39 Candesartan cilexetil was well tolerated 
and was devoid of clinically relevant biochemical, hemato-
logical or cardiac effects. Only 12% of adverse events were 
judged to be causally related to the drug and only about 5% 
of patients withdrew from therapy due to adverse events. 
The most   common adverse events were typical of patients 
with hypertension in general. Most adverse events appeared 
during the first 3 months of treatment and their incidence 
decreased steadily with time. Tolerability was unrelated 
to gender, age (,65 versus $65 years) or dosage. These 
results demonstrate that candesartan cilexetil maintains its 
antihypertensive effects and tolerability during long-term 
administration.40
Candesartan does not inhibit ACE, also known as 
kininase II, the enzyme that converts angiotensin I to 
angiotensin II and degrades bradykinin, nor does it bind to 
or block other hormone receptors or ion channels known to 
be important in cardiovascular regulation. It therefore leads 
to fewer side effects, particularly the troublesome cough with 
ACE inhibitors.
Clinical indications
Candesartan is currently licensed for the treatment of hyper-
tension and HF with reduced left ventricular function. How-
ever, candesartan may have wider benefits in the treatment 
of renal disease and diabetic retinopathy.
Hypertension
Candesartan therapy causes a dose-dependent reduction 
in arterial blood pressure. Systemic peripheral resistance 
is decreased, while heart rate, stroke volume and cardiac 
output are not significantly affected.41 No first dose hypoten-
sion was observed during controlled clinical trials with 
candesartan.
Most of the antihypertensive effect develops within 
2 weeks of initial dosing, with a full effect seen by 4 weeks. 
With once-daily dosing, the BP effect was maintained over 
24 hours with trough to peak ratios of more than 80%. As 
once-daily monotherapy, candesartan cilexetil 8 mg is as 
effective as enalapril 10–20 mg, amlodipine 5 mg or hydro-
chlorothiazide 25 mg, and candesartan cilexetil 16 mg is 
more effective than losartan 50 mg.42
The results of a number of head-to-head clinical 
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etil and irbesartan may be more effective than the losartan.43 
Ambulatory BP studies have clarified the relative duration 
of antihypertensive action of the AT1 receptor blockers. In 
particular, studies mimicking the common event of a missed 
or delayed tablet show that the antihypertensive effect of 
candesartan cilexetil extends well beyond the 24 h dosing 
interval, while the effect of losartan declines rapidly over 
this period.
Candesartan cilexetil has additional BP lowering effects 
when added to hydrochlorothiazide.44   Candesartan/hydro-
chlorothiazide (CC/HCTZ) combination and   amlodipine 
were equally effective in reducing BP in patients with hyper-
tension not controlled by monotherapy, but CC/HCTZ was 
better tolerated.45 After 8 weeks of   treatment both regimens 
reduced mean trough BP by similar amounts: mean sitting 
SBP/DBP reductions were -15.4/-11.9 mmHg for CC/HCTZ 
and –15.7/-12.0 mmHg for amlodipine (group differences, 
P = 0.835/0.963). The BP of 84.2% of patients on CC/HCTZ 
and 84.5% on amlodipine was controlled (sitting DBP , 90 
mmHg and sitting SBP , 140 mmHg) (P = 1.00). Six (5.9%) 
patients on CC/HCTZ and 18 (17.6%) on amlodipine dis-
continued treatment, including one (1%) and 12 (11.8%), 
respectively, owing to adverse events (P , 0.001). The most 
common adverse event was peripheral edema, which occurred 
in two patients on CC/HCTZ and 19 on amlodipine. Other 
trials have confirmed the safety and efficacy of CC/HCZ 
combination therapy in the treatment of severe hypertension 
(DBP . 110 mmHg).46,47
The tolerability of candesartan was similar in men and 
women and in patients older and younger than 65.48 Candesar-
tan was effective in reducing BP regardless of race, although 
the effect was slightly lower in black (usually a low-renin 
population) than in white people.49
Hypertension endpoint studies
While the data on the antihypertensive benefits of cande-
sartan are compelling in terms of efficacy, there are fewer 
reported hard endpoint clinical trials. The Study on Cogni-
tion and Prognosis in the Elderly (SCOPE) enrolled 4964 
patients aged 70–89 years. Patients were randomly assigned 
to double-blind candesartan or placebo with open-label 
antihypertensive therapy (mostly thiazide diuretics) added 
as needed to control blood pressure. Approximately 35% of 
patients had isolated systolic hypertension (SBP . 60 mmHg, 
DBP , 90 mmHg). Blood pressure fell by 21.7/10.8 mmHg 
in the candesartan group and by 18.5/ 9.2 mmHg in the con-
trol group. Candesartan-based therapy was associated with a 
nonsignificant 10.9% relative risk reduction (242 versus 268 
events) in the primary composite endpoint of cardiovascular 
death, nonfatal stroke and nonfatal myocardial infarction. 
There were significant reductions in nonfatal stroke (27.8%, 
P = 0.04), and all stroke (23.6%, P = 0.056) but no differences 
in myocardial infarction and cardiovascular mortality in the 
candesartan-treated cohort. The proportions of patients who 
had a significant cognitive decline or developed dementia 
were similar in the two treatment groups.50 In a predefined 
subgroup analysis of patients with isolated systolic hyperten-
sion, candesartan-based therapy was associated with a 42% 
risk reduction (P = 0.049 adjusted for baseline risk) despite 
similar BP control (difference between treatments 2/1 mmHg; 
P = 0.101 and 0.064).51
The Acute Candesartan Cilexetil Therapy in Stroke Sur-
vivors (ACCESS) study was a Phase II multicenter double-
blind placebo controlled trial designed to assess the safety 
of modest BP reduction by candesartan cilexetil in the early 
treatment of stroke.52 Five hundred patients were enrolled. 
The trial was stopped prematurely when 342 patients (339 
valid) had been randomized because of an imbalance in 
endpoints. However, the trial reported that, in the absence of 
blood pressure lowering, candesartan treatment for 7 days, 
started within 24 hours of motor deficit associated with 
stoke, reduced the cumulative 12-month mortality rate (7.2 
and 2.9% for placebo and candesartan, respectively) and 
vascular events (18.7 and 9.8% for placebo and candesartan, 
respectively). Demographic data, cardiovascular risk factors, 
and BP on admission, on study onset, and within the whole 
study period were not significantly different between the two 
groups, nor were there significant differences in concomitant 
medication and in number or type of side effects. The authors 
concluded that early initiation of low-dose candesartan was 
safe in acute stroke, and may provide therapeutic benefits. BP 
reduction is clearly important in secondary prevention and 
candesartan is a safe and effective therapeutic option.
These results have not been confirmed in the recently 
published and much larger PRoFESS trial of another ARB, 
telmisartan, in the management of acute stroke.53
The evidence of added benefit from the use of ARB 
therapy in patients with recent stroke disease is therefore 
not compelling at present but further, larger scale, studies on 
the initiation of ARB therapy within 24 hours of the onset of 
motor deficit are needed.
Prehypertension
Prehypertension is very prevalent, affecting over 30% 
of the adult population. The mechanism of elevated risk 
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sion is presumed to be the same as that of hypertension. 
The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure54 emphasizes the importance of lifestyle 
measures, with weight control and exercise as the mainstay 
of therapy, except for higher risk people such as those with 
diabetes, chronic kidney disease, and known coronary 
artery disease.
The Trial of Preventing Hypertension (TROPHY) study 
recruited people with ‘high normal blood pressure’ who 
were randomized to 4 years of placebo (n = 381) or 2 years 
of 16 mg/day of candesartan (n = 391) followed by 2 years 
of placebo. At 2 years, there was a 26.8% absolute and a 
66.3% relative risk reduction (P , 0.0001) of hypertension 
in the candesartan-treated group. At study end, the former 
candesartan group had a 9.8% absolute and a 15.6% relative 
risk reduction (P , 0.007) of hypertension. The treatment 
was well tolerated. The TROPHY trial is the first trial of 
pharmacological intervention in people with prehyperten-
sion. As such it has stimulated debate about this approach,55,56 
but, since the clinical and financial implications of treating 
over one third of the adult population are substantial, larger 
scale clinical outcome trials are needed before this can be 
widely advocated.
Chronic heart failure
The central role of RAAS system blockade in the treatment 
of chronic congestive heart failure is well established. There 
is a large body of endpoint clinical trial data supporting the 
benefits of ACE inhibitors in heart failure management, 
with reported reductions of 23% in total mortality, of 35% 
in a combined endpoint of mortality or hospitalization for 
heart failure.57 A recently published meta-analysis of 18,160 
patients enrolled in nine trials which met the inclusion criteria 
reported a 2.3% increased risk of developing any adverse 
effect (P , 0.00001). Risks predictably included hypoten-
sion, worsening renal function and hyperkalemia. The authors 
concluded that ARBs should not routinely be added to ACE 
inhibitor therapy for left ventricular dysfunction. If chosen in 
higher risk patients, for example those with ejection fractions 
below 40% and continued symptoms despite ACE inhibitor 
and β-blocker therapy,58 the combination strategy warrants 
closer patient monitoring to detect adverse effects.
Atrial fibrillation
Further analysis of CHARM results also shows a reduced 
incidence of atrial fibrillation in patients on candesartan. Of 
the 7601 patients in the overall CHARM population, 6379 
did not have atrial fibrillation at baseline and these patients 
were included in the new secondary analysis. This showed at 
a median follow-up of 37.7 months that 5.55% of patients in 
the candesartan group were reported to have experienced one 
or more episodes of atrial fibrillation compared with 6.74% 
in the placebo group (P = 0.048). The relative risk reduction 
for the incidence of atrial fibrillation was 17.7% for cande-
sartan treatment compared with placebo. This reduction was 
observed across all groups of heart failure.59 These results 
are consistent with those from previous trials, which have 
indicated that ARBs may reduce atrial fibrillation.60,61
According to Roland E Schmieder et al RAS inhibition 
is an emerging treatment for the primary and secondary 
prevention of AF but acknowledges the fact that some 
of the primary prevention trials were post-hoc analyses. 
Further areas of uncertainty include potential differences 
among specific RAS inhibitors and possible interactions 
or synergistic effects with antiarrhythmic drugs. In fact the 
authors reviewed published clinical trial data on the effects 
of renin-angiotensin system (RAS) inhibition for the pre-
vention of atrial fibrillation (AF), aiming to define when 
RAS inhibition is most effective; but individual studies 
examining the effects of RAS   inhibition on AF prevention 
have reported controversial results.   Overall, RAS inhibition 
reduced the odds ratio for AF by 33% (P , 0.00001), but 
there was substantial heterogeneity among trials. In primary 
prevention, RAS inhibition was effective in patients with 
heart failure and those with hypertension and left ventricular 
hypertrophy but not in post-myocardial infarction patients 
overall. In secondary prevention, RAS inhibition was often 
administered in addition to antiarrhythmic drugs, including 
amiodarone, further reducing the odds for AF recurrence after 
cardioversion by 45% (P = 0.01) and in patients on medical 
therapy by 63% (P , 0.00001).62
Diabetes prevention
It has been suggested that RAAS blockade may reduce the 
development of type 2 diabetes by hemodynamic effects, such 
as improved delivery of insulin and glucose to peripheral skel-
etal muscle, and nonhemodynamic effects, including direct 
effects on glucose transport and insulin signaling pathways, 
all of which decrease insulin resistance.63 Experimental data 
using mouse models showed that candesartan prevented dete-
rioration of glucose tolerance by providing protection against 
progressive β-cell damage in diabetes.64 One systematic 
literature search identified 11 trials which enrolled 66,608 
patients. ACE inhibitor or ARB therapy was associated with 
a 22% reduction in new-onset type 2 diabetes.65 A number Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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of large clinical trials of RAAS blockade have also reported 
reductions in new-onset diabetes of between 14 and 34%.66 
A recent meta-analysis was undertaken to assess the effects 
of antihypertensive agents on incident diabetes. A systematic 
review identified 48 randomized groups of 22 clinical trials 
with 143,153 participants who did not have diabetes at ran-
domization and so were eligible for inclusion. The association 
of antihypertensive drugs with incident diabetes is therefore 
lowest for ARB and ACE inhibitors, followed by CCB and 
placebo, β-blockers and diuretics in rank order.67 The CASE 
J trial, a large-scale outcome study in Japan comparing the 
ARB candesartan cilexetil and the CCB amlodipine showed 
a reduction in new diabetes as a secondary outcome. Pre-
specified analysis of new-onset diabetes showed a significant 
reduction of 36% with candesartan compared with amlo-
dipine (HR, 0.64; 95% CI: 0.43–0.97; P = 0.030). Stratified 
analysis revealed that this effect was greatest in the obese 
patients (62% risk reduction).68 A similar effect was noted as 
a secondary outcome in HIJ-Create, which showed new onset 
rates of diabetes with candesartan and non-ARB standard 
therapy as 1.1% and 2.9%, respectively (P = 0.027).69
With respect to candesartan, CHARM included the devel-
opment of type 2 diabetes as a secondary outcome in those 
patients who did not have a diagnosis of diabetes at entry.53 
Patients received candesartan (target of 32 mg once daily) or 
matching placebo for 2–4 years. One hundred and sixty-three 
(6.0%) patients in the candesartan group developed diabetes, 
compared with 202 (7.4%) in the placebo group, a 28% rela-
tive risk reduction (P = 0.020). The composite endpoint of 
death or diabetes occurred in 692 (25.2%) and 779 (28.6%) 
in the candesartan and placebo groups, respectively (HR, 
0.86; 95% CI: 0.78–0.95; P = 0.004).
A further small study70 suggests an improved early-
phase insulin response in patients with hypertension with 
impaired glucose tolerance in association with candesartan 
treatment, which may delay or prevent the development of 
insulin resistance and diabetes. Patients with hypertension 
and impaired glucose tolerance were randomly divided into 
two groups: group A (n = 6), who received 8 mg/day of oral 
candesartan for 3 months, and controls (n = 6). Before and 
after administration, a 75 g oral glucose tolerance test was 
conducted to compare various parameters. No significant dif-
ferences in age, body mass index (BMI), SBP, DBP, fasting 
glucose, or fasting immunoreactive insulin were identified 
between the groups before administration. After 3 months, 
there were no significant changes in BMI, SBP and DBP for 
the controls and in BMI and DBP for group A. However, 
SBP was significantly decreased from 144 ± 2.6 mmHg to 
125 ± 4.6 mmHg in group A. Insulinogenic index tended 
to be slightly decreased for controls, but was significantly 
increased from 0.32 ± 0.0 to 0.47 ± 0.1 for group A.
While these studies provide support for the hypothesis 
that RAAS blockade may reduce the development of new-
onset diabetes, recent large-scale trials have failed to con-
firm this. Neither the Diabetes Reduction Approaches with 
Ramipril and Rosiglitazone Medications (DREAM) trial with 
the ACE inhibitor ramipril, in which new-onset diabetes was 
a primary endpoint, nor the very large ONTARGET found 
any benefit of ACE inhibitor or ARB therapy in the develop-
ment of diabetes. The Nateglinide and Valsartan in Impaired 
Glucose Tolerance Outcomes Research (NAVIGATOR) trial 
with valsartan is currently ongoing.71,72
There is currently insufficient evidence to support the 
hypothesis that RAAS blockade with candesartan or other 
ARBs or ACE inhibitors has a significant effect on the 
development of diabetes.
Urinary albumin excretion
RAAS system blockade is accepted as a central management 
strategy in the treatment of proteinuric renal disease. RAAS is 
believed to have a major influence on intraglomerular filtration 
pressure by preferentially regulating post-glomerular efferent 
arteriolar resistance leading to intra-glomerular hypertension 
and the potentiation of proteinuria.73 Early clinical trials in 
patients with type 1 diabetes and established renal disease 
confirmed that an ACE inhibitor based treatment strategy 
halved the rate of renal deterioration, the need for dialysis 
and death.74 Studies have also confirmed the benefits of ACE 
inhibition at the earlier microalbuminuric stage of diabetic 
nephropathy75 and also in the progression of normo- to 
microalbuminuria.76 In type 2 diabetes the IDNT77 and 
RENAAL78 trials confirm the renal benefits of irbesartan- and 
losartan-based therapies in patients with established renal 
disease, and IRMA-II data79 confirmed benefit in patients 
with type 2 diabetes and microalbuminuria. Whether ACE 
inhibitors or ARBs are superior is a matter of controversy. A 
Cochrane review in 2004 concluded that the renal benefits of 
these agents were similar but there were insufficient data to 
determine whether the ARBs had similar survival benefits to 
ACE inhibitor therapy.80 No cardiovascular outcome benefits 
were seen in the IDNT, IRMA2 and RENAAL trials.
As a potent long-acting ARB, candesartan would be 
expected to reduce urine protein excretion in a variety of 
renal diseases. Early studies in rats suggested beneficial reno-
protective effects of candesartan81 and an early comparative 
trial between candesartan and ACE inhibition confirmed Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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improvements in proteinuria, with a greater effect seen in 
the candesartan group.82
Murayama and colleagues83 reported the benefits of cande-
sartan in patients with early kidney disease independent of its 
antihypertensive effect. Fifty-two patients with type 2 diabe-
tes with normo- or microalbuminuria participated. Nineteen 
patients with high normal and mild hypertension received 
low-dose candesartan (4 mg once daily; candesartan group), 
and 33 patients did not receive candesartan (control group). 
Blood pressure, urinary albumin excretion, transferrin, and 
type IV collagen (expressed as urinary creatinine index) and 
plasma parameters were determined at baseline and at 2, 6, 12 
and 18 months after the start of candesartan therapy. Baseline 
parameters were similar in both groups. Candesartan treat-
ment decreased the higher baseline SBP to the level of the 
control group. In the control group, urinary albumin excretion 
increased significantly at 18 months compared with baseline, 
while no changes in urinary albumin excretion were reported 
in the candesartan group.
The antiproteinuric effects of candesartan are dose 
dependent. In a short-term study of 23 patients with hyper-
tension, type 2 diabetes and nephropathy the effect of four 
treatment doses of 8, 16 or 32 mg candesartan compared 
with placebo were compared during four treatment peri-
ods each lasting 2 months. The trial was double blind and 
patients received treatment doses in random order. All three 
candesartan doses significantly reduced albuminuria and 
24-hour BP compared with placebo. Mean (95% CI) reduc-
tions in albuminuria were 33% (21–43), 59% (52–65), and 
52% (44–59) for the 8, 16 and 32 mg dosing schedules, 
respectively. Higher doses (16 and 32 mg) were associated 
with a significantly greater antiproteinuric effect, but there 
were no differences in reduction of BP between the three   
doses.84
Several studies have investigated whether supra-maximal 
doses of candesartan may have additional effects to reduce 
proteinuria. In a pilot study in 2004, Weinberg and col-
leagues85 reported benefits from doses up to 160 mg daily, 
which is five times higher than the maximal recommended 
dose. No safety or tolerability issues were reported. A signifi-
cant relative reduction of 30% was reported using a 64 mg 
daily dose of candesartan in 32 patients with diabetic or 
nondiabetic renal disease when compared with 16 mg daily 
dosing.86 Finally, a recent report suggests there are benefits 
of using supramaximal doses of candesartan in reducing 
proteinuria.87 Reductions of 33% were seen using doses of 
64 and 128 mg daily compared with 16 mg daily in a trial 
of 269 patients, mostly with diabetic nephropathy. Whether 
these reductions are associated with improved long-term 
renal protection is unknown.
Although much interest has focused on the prevention 
and treatment of diabetic renal disease, the antiprotei-
nuric effects of candesartan have also been reported in 
patients with nondiabetic renal diseases, including chronic 
glomerulonephritis,88 renal transplant recipients89 and 
patients with adult polycystic kidney disease.90
Dual blockade using ACE inhibitors and ARBs in com-
bination has received considerable interest over the last 
10 years. The Candesartan and Lisinopril Microalbuminu-
ria (CALM) trial first reported improved control of blood 
pressure and reduced proteinuria using this combination.91 
CALM was a randomized double-blind trial in 199 patients 
aged 30–75 years with type 2 diabetes, microalbuminuria 
(urinary albumin: creatinine ratio 2.5–25 mg/mmol), and 
DBP between 90 and 110 mmHg. Patients were allocated 
to one of four groups: candesartan for 24 weeks (n = 66), 
lisinopril for 24 weeks (n = 64), candesartan for 12 weeks 
with the addition of lisinopril for a subsequent 12 weeks 
(n = 34), or lisinopril for 12 weeks with the addition of can-
desartan for a subsequent 12 weeks (n = 35). At 24 weeks, 
mean DBP was lower with combination treatment (16.3 
mmHg) than with candesartan (10.4 mmHg; P = 0.003) or 
lisinopril monotherapy (10.7 mmHg; P = 0.005). Similar 
benefits were seen in SBP with combination treatment. 
Combination treatment was associated with a greater mean 
reduction from baseline in urinary albumin to creatinine ratio 
than candesartan alone (50% versus 24%; P = 0.04) but not 
lisinopril alone (50% versus 39%; P . 0.20). Since this early 
report several small, short-term studies have reported similar 
benefits.92–94 More recently the CALM-2 trial95 did not find 
any difference between lisinopril 40 mg daily compared with 
lisinopril 16 mg daily plus the addition of candesartan 16 mg 
daily during a 12-month follow-up period. Urinary albumin 
excretion remained stable through the follow-up period in 
both groups, with no significant differences between the 
two regimens.
The problem with these studies is their short follow-up, 
small numbers of study participants and the use of surrogate 
markers (BP and urine albumin secretion) rather than clini-
cally relevant hard endpoints.
Taken together these data cast significant doubt on the 
  utility of dual RAAS blockade using ACE inhibitors and ARBs, 
  particularly in patients with   low-level (,1G per day)   proteinuria. 
In patients with   high-range proteinuria, the addition of can-
desartan to ongoing ACE inhibitor treatment may be consid-
ered, but patients on this combination would require careful Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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monitoring of BP, serum potassium, proteinuria and renal 
function to ensure safety.
Retinopathy
The growing evidence of local RAAS within the eye which 
is activated in diabetes, combined with the reported benefits 
of the ACE inhibitor lisinopril in retinopathy in the EUCLID 
trial, formed the rationale for the Diabetic Retinopathy 
Candesartan Trials (DIRECT) clinical trial programme. 
Local RAS is believed to be responsible, either directly or 
via other mediators, for increased concentrations of vascular 
endothelial growth factor, a selective angiogenic and vasop-
ermeability factor implicated in the pathogenesis of diabetic 
retinopathy.
It has been suggested that inhibition of ACE or blockade 
of angiotensin II could reduce vascular endothelial growth 
factor concentrations and favourably influence the develop-
ment or progression of retinopathy.
The DIRECT programme was designed to assess whether 
candesartan could reduce the incidence and progression of 
retinopathy in type 1 diabetes and the progression of retin-
opathy in type 2 diabetes. The programme consisted of three 
randomized, double-blind, parallel-design, placebo-controlled 
trials; two in patients with type 1 diabetes and a third in patients 
with type 2 diabetes. The DIRECT-Prevent 1 trial recruited 
participants with normotensive, normoalbuminuric type 1 
diabetes without retinopathy. Participants with type 1 diabe-
tes and existing mild–moderate retinopathy were recruited to 
DIRECT-Protect 1. Participants were assigned to candesartan 
16 mg once a day or matching placebo. After 1 month the dose 
was doubled to 32 mg. The primary endpoints were incidence 
and progression of retinopathy and were defined as at least a 
two-step and at least a three-step increase on the Early Treat-
ment Diabetic Retinopathy Study (ETDRS) scale, respectively. 
New retinopathy developed in 178 (25%) participants in the 
candesartan group versus 217 (31%) in the placebo group. 
Progression of retinopathy occurred in 127 (13%) participants 
in the candesartan group versus 124 (13%) in the placebo 
group. Hazard ratio (HR for candesartan vs placebo) was 0.82 
(95% CI: 0.67–1.00; P = 0.0508) for incidence of retinopathy 
and 1.02 (95% CI: 0.80–1.31; P = 0.85) for progression of 
retinopathy.
Final ETDRS level was more likely to have improved with 
candesartan treatment in both DIRECT-Prevent 1 (OR, 1.16; 
95% CI: 1.05–1.30; P = 0.0048) and DIRECT-Protect 1 (OR, 
1.12; 95% CI:1.01–1.25; P = 0.0264). The investigators 
hypothesized that candesartan reduces the incidence of 
retinopathy, although they did not see a beneficial effect on 
retinopathy progression in type 1 diabetes.96
The DIRECT-Protect 2 programme studied people with 
type 2 diabetes and retinopathy at enrolment. The study 
examined whether candesartan treatment could slow the pro-
gression and, secondly, induce regression of retinopathy.
Patients with type 2 diabetes who were normoalbumin-
uric, normotensive or treated hypertensive with mild to 
moderately severe retinopathy were recruited and assigned 
to candesartan 16 mg once a day or placebo which was sub-
sequently increased to 32 mg.
A total of 161 (17%) patients in the candesartan group 
and 182 (19%) in the placebo group had progression of 
  retinopathy by three steps or more on the ETDRS scale. 
The risk of progression of retinopathy was nonsignificantly 
reduced by 13% in patients on candesartan compared with 
those on placebo (HR, 0.87; 95% CI: 0.70–1.08; P = 0.20). 
Regression on active treatment was increased by 34% (HR, 
1.34; 95% CI: 1.08–1.68; P = 0.009). An overall change 
towards less severe retinopathy by the end of the trial was 
observed in the candesartan group (OR, 1.17; 95% CI: 
1.05–1.30; P = 0.003).
Hence the investigators suggested that treatment with 
  candesartan in patients with type 2 diabetes and mild to moder-
ate retinopathy might induce improvement of retinopathy.97
The DIRECT trial programme provides reassurance on the 
long-term safety of candesartan in a large patient population, 
with no reported differences between treatment groups.
My evidence
In a recent my paper a population of 154 patients aged 40 
to 66 years, was studied,  with WHO I-II stage essential 
hypertension, and electrocardiographic left ventricular 
Table 3 Functional capacity at the various treatment steps (mean ± SD)
Pl Pl + Asp Can Can + Asp
Oxygen consumption at peak exercise (ml/min/kg) 15 ± 3.5 14 ± 5.6 17 ± 3.2* 17.1 ± 3.1*
Dead space/Tidal volume ratio 0.21 ± 0.03 0.22 ± 0.06 0.18 ± 0.04* 0.18 ± 0.04*
exercise tolerance time(s) 514 ± 186 515 ± 132 580 ± 169* 602 ± 26*
Notes: *Difference from Pl and from Pl+Asp is significant at P , 0.01. Copyright © 2009, John wiley and Sons. Reproduced with permission from De Rosa ML, Chiariello M. 
Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial. J Clin Hypertens. 2009;11(4):192–200.
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hypertrophy. They were randomized to receive placebo, can-
desartan (32 mg), each of these plus aspirin (300 mg/day), or 
the same preparations in a reverse order, each for 3 weeks, 
with a 3-week wash out period between treatments. Maximal 
workload and oxygen reserve were measured cardiopulmo-
nary exercise test, 24-hour ambulatory BP, LV mass index by 
echocardiography according to American Heart Association 
recommendations, at the end of each treatment.
The patients did not achieve the maximal workload as 
predicted by age, gender and weight and height [116 (99–133) 
vs 132 (116–149) Watts, P = 0.01]. This impaired exercise 
capacity, calculated as the ratio between achieved and pre-
dicted maximal workload was in multiple regression analysis 
related to lower oxygen reserve (r = 0.49, P , 0.001), and 
the lower oxygen reserve to higher echo LVH (β = −0.34), 
respectively.
Candesartan alone or with aspirin caused an improvement 
of VO2 and exercise tolerance, which was absent in controls 
(Tables 3–4).
Considering that hypertrophy and remodeling in patients 
with untreated hypertension have been associated with 
impaired exercise capacity, candesartan was tested to see 
whether it improved exercise peak oxygen volume (VO2) in 
this population.
Thus, hypertensives cannot achieve the predicted 
maximal workload. This impaired exercise capacity was 
related to lower oxygen reserve while peak VO2 may 
be (NYHA class) the strongest prognostic factor in this   
population.
Furthermore, candesartan may represent an alternative 
or even an advancement in hypertensives for its efficacy on 
exercise VO2 and exercise tolerance, without antagonism 
by aspirin.98
Conclusions
Candesartan has shown benefit in the treatment of hyper-
tension. It has been shown to be more effective than losar-
tan43 in a number of studies. Candesartan has also shown 
effectiveness when combined with hydrochlorothiazide and 
good tolerability in this setting.45 This combination has been 
shown to be both safe and effective in the treatment of severe 
hypertension.46,47
As well as showing reduction in blood pressure, candesar-
tan has also shown benefits in terms of hypertension endpoint 
studies. SCOPE showed significant reductions in nonfatal 
stroke (27.8%; P = 0.04) and all stroke (23.6%; P = 0.049).51 
ACCESS looked at the early initiation of candesartan fol-
lowing stroke. This trial reported that, despite the absence of 
BP lowering, candesartan treatment for 7 days, started within 
24 hours of motor deficit associated with stoke, reduced the 
cumulative 12-month mortality rate (7.2 and 2.9% for placebo 
and candesartan, respectively) and vascular events (18.7 and 
9.8% for placebo and candesartan, respectively).52
Candesartan has also been studied in the prevention of 
hypertension in the setting of prehypertension. TROPHY 
is the first such trial in this group of patients. It showed 
a 9.8% absolute and a 15.6% relative risk reduction 
(P , 0.007) of hypertension. As this is the first such trial, 
others will be required to further validate this approach 
but the implications are far reaching.55,56
One of the major areas of importance for candesartan is in 
the treatment of heart failure, with a reduced ejection fraction 
below 40%. CHARM showed reduction in cardiovascular 
death and congestive heart failure hospitalization versus 
placebo when both used as an alternative to ACE inhibitor 
therapy (HR = 0.7; P , 0001) or when added to ACE inhibitor 
therapy (HR = 0.85; P , 0.01).58 Interestingly, CHARM also 
Table 4 Maximal exercise blood pressure and heart rate and oxygen reserve and LVM at the various treatment
Steps (mean ± SD) Pl Pl + Asp Can Can + Asp
Maximal systolic BP (mmHg) 202 ± 4 203 ± 4 192 ± 5* 190 ± 4*
Δ systolic BP 55 ± 4 56 ± 3 58 ± 5 58 ± 4
Maximal diastolic BP (mmHg) 99 ± 5 92 ± 2 85 ± 3* 78 ± 2*
Δ diastolic BP 5 ± 5 5 ± 4 6 ± 3 6 ± 4
Maximal Heart Rate (b/min) 161 ± 4 166 ± 2 170 ± 5* 176 ± 3*
Δ Heart Rate 84 ± 4 84 ± 3 96 ± 4* 98 ± 4*
VO2 rest/mass (ml/kg/min) 4 ± 3 4 ± 2 4 ± 4 4 ± 1
LV mass (g) 170 ± 4 170 ± 8 169 ± 2* 169 ± 3*
Oxygen reserve (ratio) 3.8 ± 0.3 3.5 ± 0.2 4 3 ± 0.4* 4.3 ± 0.1*
Δ effort (Borg scale) 19 ± 0.3 19 ± 0.2 19 ± 0.4 19 ± 0.2
Notes: Δ = change with exercise *Difference from Pl and from Pl + Asp is significant at P , 0.01. Copyright © 2009, John wiley and Sons. Reproduced with permission from 
De Rosa ML, Chiariello M. Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial. J Clin Hypertens. 
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showed that candesartan reduced the incidence of new atrial 
fibrillation.59
Candesartan has shown a benefit in diabetes   prevention. 
Both the CASE trial and HIJ-Create have shown a reduction in 
new incidence of diabetes in patients using candesartan. 
CASE-J showed a significant effect when compared with 
amlodipine (HR, 0.64; 95% CI: 0.43–0.97; P = 0.030) and 
HIJ-Create showed reduced incidence compared with non-
ARB treatment (P = 0.027).67,68
Data also support its use in patients with proteinuric 
renal disease as an alternative should an ACE inhibitor not 
be tolerated, although it should be remembered that it does 
not have a specific licence for this indication. ARBs have 
been shown to be beneficial in patients with established renal 
disease (RENALL, IDNT) and have shown similar benefits 
to ACE inhibitor therapy.77,78 Dual blockade using both ACE 
inhibitors and ARBs has been tried. CALM showed a larger 
reduction in BP with the combination of candesartan and 
lisinopril than with monotherapy (13.3 mmHg combination; 
10.4 mmHg, P = 0.003 candesartan; 10.7 mmHg, P = 0.005 
lisinopril). There was a reduction from baseline in urinary 
albumin to creatinine ratio when candesartan was used in 
combination versus alone (50% versus 24%; P = 0.04).91
The recent DIRECT study supports the use of candesartan 
in patients with early stage retinopathy. Candesartan reduced 
the incidence of retinopathy in DIRECT-Prevent 1. DIRECT 
Protect 2 showed a change towards less severe retinopathy in 
the candesartan group versus the placebo group (OR, 1.17; 
95% CI: 1.05–1.30; P = 0.003).96,97
Overall candesartan is a very safe, well tolerated drug 
from the group of ARBs. Its pleiotropic effects ensure that 
it has wide-ranging implications for clinical use with an 
ever expanding wealth of evidence to support its ongoing 
and widening usage.
Hypertensives had lower measures of peakVO2, oxygen 
reserve and heart rate at maximal exercise than predicted by 
age, gender, weight and height.
In my crossover and placebo-controlled study in patients 
with mild to moderate hypertension, candesartan mono 
therapy produces a significantly lower arterial BP than pla-
cebo or placebo plus aspirin at week 3 of treatment while a 
combination of candesartan and aspirin yielded a better physi-
cal performance and exercise oxygen uptake compared with 
either drug alone. Furthermore, candesartan may represent an 
alternative in hypertensive patients for its efficacy on exercise 
peak VO2 and exercise tolerance, because of similar efficacy 
of ACE inhibitor for exercise performance and less exposure 
to the counteracting activity of aspirin.98
ARBs have established themselves as versatile agents for 
the treatment of a variety of conditions throughout the CV 
continuum. While the accumulation of evidence with ARBs 
has involved clinical trials with a number of different indi-
vidual agents, in addition to candesartan, other ARBs such 
as valsartan, telmisartan, and losartan have demonstrated 
benefits on major CV endpoints. Pharmacological studies have 
highlighted the differences among AT1-receptor blockers, and 
confirmed the tight receptor binding and long-acting properties 
of candesartan.
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